Acquisitions CSC acquisitions (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	May. 08, 2014
Business Acquisition [Line Items]
Revenues	$ 7,560	$ 5,888	$ 5,867	$ 3,172	$ 5,276	$ 4,118	$ 4,489	$ 4,056	$ 22,487,566	$ 17,938,790	$ 14,668,455
Common stock, shares, issued (shares)												5,329,593
Business Acquisition, Transaction Costs												$ 33,500,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents												51,000
Business Combination, Acquired Receivables, Fair Value												45,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets												19,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment												1,041,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other												201,000
Goodwill	7,013,315				25,209,336				7,013,315	25,209,336		14,092,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill												34,290,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable												333,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities												2,014,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent												13,901,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net												33,491,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High												90,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net												19,400,000
Equity Issued in Business Combination, Fair Value Disclosure												21,600,000
Business Combination, Contingent Consideration, Liability	$ 0				$ 18,260,000				$ 0	$ 18,260,000		$ 11,900,000
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders	$ (0.59)	$ (0.21)	$ (0.38)	$ (0.51)	$ (0.32)	$ (0.48)	$ (0.40)	$ (0.49)	$ (1.67)	$ (1.68)	$ (1.90)
Net loss									$ (81,010,501)	$ (55,466,246)	$ (39,485,334)
Net Income (Loss) Attributable to Parent	$ (33,197)	$ (11,376)	$ (17,126)	$ (19,187)	$ (11,612)	$ (16,974)	$ (12,605)	$ (13,682)
NeoStem, Inc. [Member]
Business Acquisition [Line Items]
Revenues										$ 17,939,000	$ 14,668,000
Basic and diluted loss per share attributable to Caladrius Biosciences, Inc. common stockholders										$ (1.68)	$ (1.90)
Net loss										$ (55,467,000)	$ (39,485,000)
Net Income (Loss) Attributable to Parent										(54,873,000)	(38,981,000)
NeoStem Oncology [Member]
Business Acquisition [Line Items]
Business Acquisition, Pro Forma Revenue										18,649,000	15,471,000
Business Acquisition, Pro Forma Net Income (Loss)										(57,964,000)	(44,790,000)
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual										$ (57,371,000)	$ (44,286,000)
Business Acquisition, Pro Forma Earnings Per Share, Diluted										$ (1.51)	$ (1.71)